View source for Template:Relative oral potencies of estrogens

{| style="font-size: small; margin-left: auto; margin-right: auto; border: none;" class="wikitable sortable mw-collapsible {{{state<includeonly>|mw-collapsed</includeonly>}}}"
|+ class="nowrap" style="font-size: 105%;" | {{Navbar|Relative oral potencies of estrogens|mini=y}} Relative oral potencies of estrogens
|-
! Estrogen !! data-sort-type="number" | {{abbrlink|HF|Hot flashes}} !! data-sort-type="number" | {{abbrlink|VE|Vaginal epithelium}} !! data-sort-type="number" | {{abbrlink|UCa|Urinary calcium}} !! data-sort-type="number" | {{abbrlink|FSH|Follicle-stimulating hormone}} !! data-sort-type="number" | {{abbrlink|LH|Luteinizing hormone}} !! data-sort-type="number" | {{abbrlink|HDL|High-density lipoprotein}}-{{abbrlink|C|Cholesterol}} !! data-sort-type="number" | {{abbrlink|SHBG|Sex hormone-binding globulin}} !! data-sort-type="number" | {{abbrlink|CBG|Corticosteroid-binding globulin}} !! data-sort-type="number" | {{abbrlink|AGT|Angiotensinogen}} !! data-sort-type="number" | {{abbr|Liver|Ratio of liver estrogenic effects to general/systemic estrogenic effects)}}
|-
| {{No selflink|Estradiol (medication)|Estradiol}} || 1.0 || 1.0 || 1.0 || 1.0 || 1.0 || 1.0 || 1.0 || 1.0 || 1.0 || 1.0
|-
| {{No selflink|Estrone (medication)|Estrone}} || ? || ? || ? || 0.3 || 0.3 || ? || ? || ? || ? || ?
|-
| {{No selflink|Estriol (medication)|Estriol}} || 0.3 || 0.3 || 0.1 || 0.3 || 0.3 || 0.2 || ? || ? || ? || 0.67
|-
| {{No selflink|Estrone sulfate (medication)|Estrone sulfate}} || ? || 0.9 || 0.9 || 0.8–0.9 || 0.9 || 0.5 || 0.9 || 0.5–0.7 || 1.4–1.5 || 0.56–1.7
|-
| {{No selflink|Conjugated estrogens}} || 1.2 || 1.5 || 2.0 || 1.1–1.3 || 1.0 || 1.5 || 3.0–3.2 || 1.3–1.5 || 5.0 || 1.3–4.5
|-
| {{No selflink|Equilin sulfate}} || ? || ? || 1.0 || ? || ? || 6.0 || 7.5 || 6.0 || 7.5 || ?
|-
| {{No selflink|Ethinylestradiol}} || 120 || 150 || 400 || 60–150<!--120--> || 100 || 400 || 500–600 || 500–600 || 350 || 2.9–5.0
|-
| {{No selflink|Diethylstilbestrol}} || ? || ? || ? || 2.9–3.4 || ? || ? || 26–28 || 25–37 || 20 || 5.7–7.5
|- class="sortbottom"
| colspan="11" style="width: 1px; background-color:#eaecf0; text-align: center;" | {{hidden|header=Sources and footnotes|content='''Notes:''' Values are ratios, with estradiol as standard (i.e., 1.0). '''Abbreviations:''' {{abbr|HF|Hot flashes}} = Clinical relief of [[hot flash]]es. {{abbr|VE|Vaginal epithelium}} = Increased [[cell proliferation|proliferation]] of [[vaginal epithelium]]. {{abbr|UCa|Urinary calcium}} = Decrease in {{abbrlink|UCa|urinary calcium}}. {{abbr|FSH|follicle-stimulating hormone}} = Suppression of {{abbrlink|FSH|follicle-stimulating hormone}} levels. {{abbr|LH|luteinizing hormone}} = Suppression of {{abbrlink|LH|luteinizing hormone}} levels. {{abbr|HDL|high-density lipoprotein}}-{{abbr|C|cholesterol}}, {{abbr|SHBG|sex hormone-binding globulin}}, {{abbr|CBG|corticosteroid-binding globulin}}, and {{abbr|AGT|angiotensinogen}} = Increase in the serum levels of these [[liver protein]]s. Liver = Ratio of liver estrogenic effects to general/systemic estrogenic effects (hot flashes/[[gonadotropin]]s). '''Sources:''' <noinclude><ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 |issue=Suppl 1 |pages=3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | url = http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf}}</ref><ref name="WolfSchneider2013">{{cite book |vauthors=Göretzlehner G |chapter=Wirkspektrum unterschiedlicher Östrogene |veditors=Wolf AS, Schneider HP |title=Östrogene in Diagnostik und Therapie |language=de |chapter-url=https://books.google.com/books?id=IArLBgAAQBAJ&pg=PA78 |date=1990 |publisher=Springer-Verlag |isbn=978-3-642-75101-1 |pages=78–}}</ref><ref name="KaufmannCosta2013">{{cite book |veditors=Kaufmann M, Costa SD, Scharl A |title=Die Gynäkologie |language=de |url=https://books.google.com/books?id=1pwiBgAAQBAJ&pg=PA105 |date=2013 |publisher=Springer-Verlag|isbn=978-3-662-11496-4|pages=105–}}</ref><ref name="Kuhl1997">{{cite journal|last1=Kuhl|first1=H.|title=Metabolische Effekte der Östrogene und Gestagene |trans-title=Metabolic Effects of Estrogens and Progestogens |journal=Der Gynäkologe |language=de |volume=30 |issue=4 |date=April 1997 |pages=357–369 |issn=0017-5994 |doi=10.1007/PL00003042}}</ref><ref name="ElleringtonWhitcroft1994">{{cite book |vauthors=Ellerington MC, Whitcroft SI, Whitehead MI |chapter=Therapeutic and Preventive Aspects of Estrogen and Progesterone Therapy |pages=269–285 |veditors=Lorrain J, Plouffe L Jr, Ravnikar VA, Speroff L, Watts NB |title=Comprehensive Management of Menopause |year=1994 |issn=0178-0328 |doi=10.1007/978-1-4612-4330-4_26 |isbn=978-1-4612-4330-4}}</ref><ref name="van KeepUtian1982">{{cite conference |vauthors=van Keep PA, Utian WH, Vermeulen A |title=Potency and hepato-cellular effects of oestrogens after oral, percutaneous, and subcutaneous administration |pages=103–125 |veditors=van Keep PA, Utian WH, Vermeulen A |series=The Controversial Climacteric |conference=Third International Congress on the Menopause, held in Ostend, Belgium, in June 1981, under the auspices of the International Menopause Society |year=1982 |doi=10.1007/978-94-011-7253-0_12 |isbn=978-94-011-7253-0}}</ref><ref name="WattsSharp2003">{{cite book |vauthors=Watts DA, Sharp HT, Peterson CM |chapter=Primary and Secondary Hypogonadism in Women |pages=471–505 |veditors=Meikle AW |title=Endocrine Replacement Therapy in Clinical Practice |doi=10.1007/978-1-59259-375-0_25 |chapter-url=https://books.google.com/books?id=CA0HCAAAQBAJ&pg=PA471 |date=2003 |publisher=Springer Science & Business Media |isbn=978-1-59259-375-0}}</ref><ref name="pmid6291391">{{cite journal |vauthors=Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, Mishell DR |title=Comparison of pharmacodynamic properties of various estrogen formulations |journal=Am. J. Obstet. Gynecol. |volume=144 |issue=5 |pages=511–518 |date=November 1982 |pmid=6291391 |doi=10.1016/0002-9378(82)90218-6}}</ref><ref name="pmid6282033">{{cite journal |vauthors=Helgason S |title=Estrogen replacement therapy after the menopause. Estrogenicity and metabolic effects |journal=Acta Obstet Gynecol Scand |volume=61 |issue=S107 |pages=1–29 |date=1982 |pmid=6282033 |doi=10.3109/00016348209155333}}</ref><ref name="pmid3338581">{{cite journal |vauthors=Lobo RA, Nguyen HN, Eggena P, Brenner PF |title=Biologic effects of equilin sulfate in postmenopausal women |journal=Fertil. Steril. |volume=49 |issue=2 |pages=234–8 |date=February 1988 |pmid=3338581 |doi=10.1016/S0015-0282(16)59708-8 |url=https://www.fertstert.org/article/S0015-0282(16)59708-8/pdf |format=PDF}}</ref></noinclude><includeonly>See template.</includeonly>}}
|}<!--
--><noinclude>{{Documentation|content=
==See also==
* [[Template:Oral potencies of estrogens]]
* [[Pharmacokinetics of estradiol#Oral administration|Pharmacokinetics of estradiol § Oral administration]]
==References==
{{Reflist}}
}}
[[Category:Medication templates]]
[[Category:Templates that generate named references]]
</noinclude>